Diamond Equity Equities Analysts Cut Earnings Estimates for ProPhase Labs, Inc. (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Diamond Equity lowered their Q1 2024 earnings per share estimates for ProPhase Labs in a research report issued on Monday, April 22nd. Diamond Equity analyst H. Diamond now forecasts that the company will post earnings per share of ($0.15) for the quarter, down from their prior estimate of ($0.11). The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.82) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at $0.04 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at ($0.10) EPS and FY2025 earnings at $0.48 EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a research report on Wednesday, February 21st.

ProPhase Labs Stock Down 4.8 %

Shares of NASDAQ:PRPH opened at $4.71 on Thursday. The stock has a market cap of $85.02 million, a price-to-earnings ratio of -4.81 and a beta of -0.29. The company has a quick ratio of 2.10, a current ratio of 2.28 and a debt-to-equity ratio of 0.29. ProPhase Labs has a 12-month low of $4.05 and a 12-month high of $9.94. The business’s 50 day moving average is $5.54 and its 200 day moving average is $5.00.

ProPhase Labs (NASDAQ:PRPH) last announced its earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. The company had revenue of $3.50 million for the quarter, compared to analysts’ expectations of $10.71 million. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%.

Institutional Trading of ProPhase Labs

A number of hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its holdings in ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after acquiring an additional 5,026 shares during the period. HighTower Advisors LLC bought a new stake in ProPhase Labs during the third quarter worth $756,000. Finally, SVB Wealth LLC bought a new stake in ProPhase Labs during the third quarter worth $208,000. 9.45% of the stock is currently owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.